Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022
April 12, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual...
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022
March 15, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
March 09, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare...
Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
February 24, 2022 08:00 ET
|
Pacira BioSciences
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 —— Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million —— More than 10 million...
Pacira to Report 2021 Financial Results on Thursday February 24, 2022
February 16, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before...
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
February 15, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7 Million
January 06, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference at 3:00 PM ET on...
Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
December 09, 2021 08:00 ET
|
Pacira BioSciences
-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow -- TAMPA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) --...